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treatment and treatment location; quality of life depends on
symptom severity (measured by the PANSS score) and side-
effects. Multivariate sensitivity analyses were carried out to
assess the robustness of results. RESULTS: An indirect compari-
son of trial data suggests that paliperidone ER (6 mg) and olan-
zapine (10 mg) are equally efﬁcacious in terms of PANSS
reduction, while the former has a superior side-effect proﬁle,
especially with respect to weight gain and sedation. In the model
this reduction in side effects on paliperidone ER translates into
(discounted) QALY gains of ~0.03 compared to olanzapine.
These health beneﬁts are realized at (discounted) incremental
costs ranging from -€3200 (-23,800 DKK) in Denmark to cost-
neutrality in Finland, suggesting either dominance or cost-
effectiveness in all four countries. The sensitivity analysis
suggests results are robust to changes in input parameters. If the
side-effect proﬁle of paliperidone ER is assumed to improve
compliance, further cost-savings and QALY gains are predicted.
CONCLUSION: Based on the available evidence and input from
local experts, paliperidone ER is predicted to dominate olanza-
pine in Sweden, Norway, Finland and Denmark. Results are
robust to changes in input parameters. Improved compliance on
paliperidone ER due to reduced side effects would further
strengthen its predicted dominance.
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OBJECTIVES: To estimate cost-effectiveness of various therapy
scenarios of treating schizophrenia with amisulprid (Solian), a
medicine of 2nd generation, in comparison with haloperidol.
METHODS: Cost-effectiveness decision model was prepared.
Treatment with amisulprid vs haloperidol was compared in fol-
lowing scenarios: Ø Scenario 1—amisulprid vs haloperidol
(with change for risperidon in case of recurrence in any arm) Ø
Scenario 2—amisulprid vs. haloperidol for 1 year (as ﬁrst line
medicine) followed by treatment with new atypical medicine
(olanzapina or risperidon) in case of recurrence. The target
population was patients suffered from chronic schizophrenia, at
the moment of exacerbation of disease. Analysis was performed
from the payers’ perspective (the National Health Budget and
patient), with a time horizon of 1 year. Estimates of effective-
ness were expressed with QALY (quality adjusted life years).
Following parameters were considered: risk of extrapyramidal
symptoms, recurrence, suicide and rates of compliance. Costs
of medicines (ﬁrst line therapy with amisulprid or haloperidol
and possibly second line therapy with olanzapina or risperidon
in case of recurrence in haloperidol arm), correcting therapy
with olanzapine or rispridone in case of recurrenece), treatment
of EPS, hospitalisation due to reccurence and outpatient con-
sultations were taken into account. RESULTS: In the scenario 1
cost of 1 QALY due to replacing standard ﬁrst line therapy
with haloperidol by amisulprid is 1601 PLN. In scenario 2,
using amisulprid during one year instead of haloperidol as ﬁrst
line therapy followed by olanzapina in case of recurrance,
brings additional costs of 275 PLN and gives additional QALY
0.056 year. Cost of quality adjusted life year is 4935 PLN.
CONCLUSION: Treatment of schizophrenia with amisulprid
during whole year, instead of haloperidol as ﬁrst line therapy
followed by risperidon in case of recurrence, is a cost effective
therapy.
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OBJECTIVES: This study determines the cost-effectiveness of 3
antipsychotics for the treatment of schizophrenia in Belgium.
METHODS: Data were retrieved from a prospective observa-
tional non randomized follow-up survey. Clinical investigators
included 293 schizophrenic patients; 136 of those patients were
assigned to Olanzapine, 129 to Risperidone and 28 to Haloperi-
dol. Patients were followed for 2 years. Total health care costs
were determined from the perspective of the public payer and
calculated by multiplying resource use with ofﬁcial tariffs; effec-
tiveness of the drugs was measured with EQ-5D. Several studies
have already compared the cost-effectiveness of different antip-
sychiotics for the treatment of schizophrenia, most of them are
however ﬂawed by methodological issues. This study therefore
uses a new method that was developed to address these limita-
tions but is not widely used yet: the net-beneﬁt regression
approach (NBRA). We show its merits by performing a cost-
effectiveness analysis of Olanzapine, Risperidone and Haloperi-
dol. RESULTS: Models were checked for selection bias but drug
choice was not endogenous; we therefore proceeded with simple
OLS regressions. The results indicate that the drugs provide
similar net monetary beneﬁts to the patient (H vs. O -4452.53
(p = 0.645), R vs. O 4439.54 (p = 0.425), R vs. H 8892.07
(p = 0.366)). When we control for several patient characteristics
R moves away further from H and O but the difference does not
reach statistical signiﬁcance (R vs. O 5857.73 (p = 0.332), R vs.
H 15233.53 (p = 0.178)). Several important patient subgroups
were also identiﬁed; they indicate that a drug performs better in
a speciﬁc patient group. Numerous sensitivity analyses conﬁrm
the robustness of the results. CONCLUSION: We conclude by
conﬁrming that the NBRA is an important enrichment to the
CEA methodology. As was demonstrated in this paper, it is often
important to correct cost-effectiveness results for patient charac-
teristics and to identify signiﬁcant patient subgroups.
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OBJECTIVES: Major depressive disorder (MDD) remains highly
under-treated and accounts for substantial health system costs.
Duloxetine, a new serotonin and norepinephrine reuptake inhibi-
tor, has been shown to be effective and safe in treatment of
depression. This study examined the cost-effectiveness of dulox-
etine vs. Selective Serotonin Reuptake Inhibitors (SSRIs: ﬂuoxet-
ine, paroxetine, sertraline, citralopram and escitalopram) and
venlafaxine extended-release (XR) from the Spanish health
system perspective. METHODS: A Markov decision model
simulated clinical management of MDD patients during six
2-month cycles in primary or secondary care. Patients on acute
treatment could experience remission, response without remis-
sion, no response, or discontinuation of initial therapy. Non–
responders and partial responders could continue therapy or
switch to another therapy. Efﬁcacy data and utility data were
derived from clinical trials. Treatment patterns were obtained
Abstracts A295
